Rockfish Bio Wins Prestigious S&B Business Award 2025

The BOKU/MUW spin-off Rockfish Bio AG was honored in May 2025 with the Science & Business Award (S&B Award) of the Rudolf Sallinger Fund, receiving the main prize of €20,000.

The S&B Award supports innovative commercialization ideas in early development stages that are based on scientific research. Its goal is to strengthen entrepreneurship and bridge the gap between science and business.

Rockfish Bio impressed the jury with its novel senolytic drug candidates, which selectively eliminate aging, dysfunctional cells (senescent cells) without harming healthy cells. These senescent cells are considered key contributors to age-related diseases.

Preclinical studies have shown promising results: treatment led to an extension of both lifespan and healthspan, as well as restoration of neuromuscular function.

“This award affirms our mission to develop effective therapies against age-related diseases,” said Dr. Ingo Lämmermann, CSO/COO of Rockfish Bio.

The founding team consists of Dr. Ingo Lämmermann and Assoc. Prof. Dr. Johannes Grillari from the Institute of Molecular Biotechnology at BOKU Vienna and the Ludwig Boltzmann Institute for Traumatology, together with Otto Kanzler and Thomas Streimelweger of red-stars.

02.06.2025